The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background: Bisphosphonates are an important component of the treatment of metastatic bone disease but more potent, oral formulations are required to improve the effectiveness and convenience of treatment. An oral formulation of the new bisphosphonate, ibandronate (BM 21.0955) has recently been developed. Patients and methods: One hundred ten patients with bone metastases (77 breast, 16, prostate,...
Purpose: The aim of this study was to evaluate pamidronate for bone painin a randomised double-blind trial and to evaluate the contribution of newmarkers of bone resorption in patients with bone metastases. Patients and methods: Fifty-two patients with painful bone metastaseswere randomised to receive a two-hour infusion of pamidronate 120 mg or anidentical infusion of saline. Four weeks later, all...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.